Envista Holdings Co. (NYSE:NVST) Receives Average Recommendation of “Hold” from Brokerages

Shares of Envista Holdings Co. (NYSE:NVST) have been given a consensus rating of “Hold” by the eleven analysts that are covering the company, MarketBeat reports. Three research analysts have rated the stock with a sell recommendation, five have issued a hold recommendation and three have issued a buy recommendation on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $29.60.

A number of equities analysts have recently commented on NVST shares. TheStreet downgraded Envista from a “c” rating to a “d+” rating in a report on Wednesday, February 7th. SVB Leerink initiated coverage on Envista in a research note on Monday, February 26th. They issued an “underperform” rating and a $19.00 target price for the company. Leerink Partnrs reiterated an “underperform” rating on shares of Envista in a research note on Monday, February 26th. William Blair lowered Envista from an “outperform” rating to a “market perform” rating in a research note on Thursday, February 8th. Finally, UBS Group initiated coverage on Envista in a research note on Friday, January 5th. They issued a “neutral” rating and a $26.00 target price for the company.

Envista Stock Performance

Envista stock opened at $20.23 on Wednesday. The stock’s 50-day moving average is $21.08 and its 200-day moving average is $22.79. The company has a market cap of $3.48 billion, a price-to-earnings ratio of -33.16, a price-to-earnings-growth ratio of 3.73 and a beta of 1.35. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.23 and a quick ratio of 1.90. Envista has a 12 month low of $18.95 and a 12 month high of $39.28.

Envista (NYSE:NVST) last released its quarterly earnings data on Wednesday, February 7th. The company reported $0.29 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.04). The firm had revenue of $645.60 million during the quarter, compared to analysts’ expectations of $638.37 million. Envista had a positive return on equity of 6.31% and a negative net margin of 3.90%. The business’s revenue for the quarter was down 2.3% compared to the same quarter last year. During the same quarter last year, the business earned $0.52 earnings per share. Equities analysts anticipate that Envista will post 1.43 earnings per share for the current year.

Institutional Investors Weigh In On Envista

A number of hedge funds have recently bought and sold shares of the business. Louisiana State Employees Retirement System grew its stake in Envista by 2.7% during the 1st quarter. Louisiana State Employees Retirement System now owns 49,400 shares of the company’s stock valued at $1,056,000 after purchasing an additional 1,300 shares in the last quarter. Canvas Wealth Advisors LLC grew its stake in Envista by 83.2% during the 1st quarter. Canvas Wealth Advisors LLC now owns 28,188 shares of the company’s stock valued at $552,000 after purchasing an additional 12,799 shares in the last quarter. Raymond James & Associates grew its position in shares of Envista by 106.3% in the 1st quarter. Raymond James & Associates now owns 842,110 shares of the company’s stock worth $18,004,000 after acquiring an additional 433,892 shares in the last quarter. State of Michigan Retirement System grew its position in shares of Envista by 2.4% in the 1st quarter. State of Michigan Retirement System now owns 42,163 shares of the company’s stock worth $901,000 after acquiring an additional 1,000 shares in the last quarter. Finally, NBC Securities Inc. grew its position in shares of Envista by 60.6% in the 1st quarter. NBC Securities Inc. now owns 8,879 shares of the company’s stock worth $189,000 after acquiring an additional 3,351 shares in the last quarter.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.